Dermatology · San Francisco area, CA
Dermatology and skin studies in San Francisco area, CA
30 recruiting studies have a site in the San Francisco area. This page includes nearby cities such as Oakland, Berkeley, San Mateo, Palo Alto.
30 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Sitryx Therapeutics Ltd
- Location
- Fremont, CA + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Sagimet Biosciences Inc.
- Location
- Fremont, CA + 17 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
Paradigm Therapeutics
- Location
- Rancho Santa Margarita, CA + 3 other US sites
- Eligibility basics
- Ages 1 mo–12
- RecruitingPhase 3
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Sanofi
- Location
- Palo Alto, CA + 14 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
- Location
- Encinitas, CA + 90 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- Fremont, CA + 20 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 1
A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
Teva Branded Pharmaceutical Products R&D LLC
- Location
- Fremont, CA + 2 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
- Location
- Fountain Valley, CA + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Eli Lilly and Company
- Location
- Fremont, CA + 8 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Eli Lilly and Company
- Location
- Fremont, CA + 17 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU…
Celldex Therapeutics
- Location
- Bakersfield, CA + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Takeda
- Location
- Fountain Valley, CA + 20 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Enveda Therapeutics
- Location
- Beverly Hills, CA + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Vanda Pharmaceuticals
- Location
- Fremont, CA + 9 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Inglewood, CA + 65 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 2
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Beijing InnoCare Pharma Tech Co., Ltd.
- Location
- Fremont, CA + 13 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company
- Location
- Los Angeles, CA + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice…
Eli Lilly and Company
- Location
- Fountain Valley, CA + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb
- Location
- Fremont, CA + 26 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
UCB Biopharma SRL
- Location
- Fremont, CA + 7 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
LEO Pharma
- Location
- Palo Alto, CA + 13 other US sites
- Eligibility basics
- Ages 6 mo–11
- RecruitingPhase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
UCB Biopharma SRL
- Location
- Apple Valley, CA + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
Oneness Biotech Co., Ltd.
- Location
- Fountain Valley, CA + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Corvus Pharmaceuticals, Inc.
- Location
- South San Francisco, CA
- Eligibility basics
- Ages 18+
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.